Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

“…Leczenie w celu zapobiegania udarom mózgu u pacjentów z migotaniem przedsionków Doustne leczenie przeciwzakrzepowe może zapobiegać większości udarów niedokrwiennych u pacjentów z AF, a także wydłużać życie [38,39,42,194,201,329,[350][351][352]. Ma ono przewagę nad brakiem leczenia lub stosowaniem kwasu acetylosalicylowego (ASA) u pacjentów z różnym profilem ryzyka udaru mózgu [353,354].…”

“…Leczenie przeciwzakrzepowe u mężczyzn z 1 punktem w skali CHA 2 DS 2 -VASc i kobiet z 2 punktami w skali CHA 2 DS 2 -VASc Do kontrolowanych prób klinicznych, w których oceniano OAC u pacjentów z AF, włączano głównie pacjentów obciążonych dużym ryzykiem udaru mózgu [38,39,42,194,201,329,351,352], a więc uzyskano silne dowody, że mężczyźni z ≥ 2 punktami w skali CHA 2 DS 2 -VASc i kobiety z ≥ 3 punktami w tej skali odnoszą korzyści z OAC. Szczęśliwie obecnie jest również coraz więcej dowodów dotyczących ryzyka udaru mózgu u pacjentów obarczonych jednym klinicznym czynnikiem ryzyka (tj.…”

Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL)

“…Studies of genetic associations with AF that have included people of African descent have suffered from small numbers of African-American individuals and findings should be interpreted with caution (41,42). There, however, are a number of multi-ethnic studies and registries with well analyzes subgroups that could also contribute to genetic associations with AF (43–49) as outlined in a recent review (50). This is the first study of genetic associations with AF in an exclusively East African population.…”

A Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation

“…Though multiple thresholds for poor and optimal TTR have been suggested, there remains no consensus and accordingly various TTR thresholds were evaluated as secondary end points. 9,12,19,23,31 All continuous variables were categorized into 6 groups split at the 10th, 25th, 50th, 75th, and 90th percentiles of the empirical distributions in order to accommodate possible nonlinear and nonmonotonic associations between continuous covariates and TTR, identify possible threshold effects, and circumvent the potential adverse impact of extreme outliers on the magnitude of regression coefficients. The 6 ordinal groups are henceforth referred to as very low (<10th percentile), low (10-25), low-normal (25-50), high-normal (50-75), high (75-90), and very high (>90).…”

“…9,21 The SAMe-TT 2 R 2 score was derived from a relatively small randomized clinical trial population, considered a limited number of candidate predictors, and demonstrated less than ideal predictive performance at external validation. 16,[21][22][23] Accordingly, the current study sought to create an improved clinical prediction model for estimating TTR among newly diagnosed AF patients for whom warfarin was initiated for anticoagulation control. The proposed prediction model was compared with the SAMe-TT 2 R 2 score with regard to predictive performance while simultaneously providing an additional external validation of the SAMe-TT 2 R 2 score.…”